Spyre Therapeutics, Inc. SYRE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $190.44M+10.9% | $171.65M-3.3% | $177.5M+0.3% | $176.99M+4.4% | $169.49M+4.1% | ||
| $51.2M+6.9% | $47.91M+3.8% | $46.15M+2.2% | $45.15M+0.6% | $44.87M-2.0% | ||
| $201.64M-3.8% | $209.56M-1.9% | $213.64M+0.7% | $212.15M-1.0% | $214.36M+2.8% | ||
| $201.64M-3.8% | $209.56M-1.9% | $213.64M+0.7% | $212.15M-1.0% | $214.36M+2.8% | ||
| -$201.64M+3.8% | -$209.56M+1.9% | -$213.64M-0.7% | -$212.15M+1.0% | -$214.36M-2.8% | ||
| $25.39M+2.0% | $24.89M+5.8% | $23.52M+0.8% | $23.33M-0.2% | $23.37M+9.7% | ||
| $27.56M-53.8% | $59.7M-7.7% | $64.66M+1,112% | $5.34M-1.7% | $5.43M+806% | ||
| $40M+300% | $10M0.0% | $10M0.0% | $10M— | $0— | ||
| -$179.44M-15.6% | -$155.22M-4.2% | -$148.98M+28.0% | -$206.81M+1.0% | -$208.93M-0.5% | ||
| $0+100% | -$15K-7.1% | -$14K-450% | $4K0.0% | $4K-92.2% | ||
| -$179.44M-15.6% | -$155.2M-4.2% | -$148.97M+28.0% | -$206.81M+1.0% | -$208.93M-0.4% | ||
| -$2.12-7.1% | -$1.98-33.8% | -$1.48+45.0% | -$2.69+12.1% | -$3.06+3.8% | ||
| -$2.12-7.1% | -$1.98+2.5% | -$2.03+31.0% | -$2.94+3.3% | -$3.04+3.8% | ||
| 263.4M+7.5% | 245.1M+7.5% | 228M+4.4% | 218.5M+7.4% | 203.5M+13.2% | ||
| 263.4M+7.5% | 245.1M+7.5% | 228M+4.4% | 218.5M+7.4% | 203.5M+13.2% | ||
| $40M+300% | $10M0.0% | $10M0.0% | $10M— | $0— | ||
| $25.39M+2.0% | $24.89M+5.8% | $23.52M+0.8% | $23.33M-0.2% | $23.37M+9.7% | ||
| —— | —— | $41.14M+329% | -$17.99M-0.3% | -$17.94M+13.4% | ||
| $190.44M+10.9% | $171.65M-3.3% | $177.5M+0.3% | $176.99M+4.4% | $169.49M+4.1% | ||
| -$201.64M+3.8% | -$209.56M+1.9% | -$213.64M-0.7% | -$212.15M+1.0% | -$214.36M-2.8% | ||
| —— | -$209.56M+1.9% | -$213.64M-0.7% | -$212.15M+1.0% | -$214.36M-2.8% | ||
| -$201.64M+3.8% | -$209.56M+1.9% | -$213.64M-0.7% | -$212.15M+1.0% | -$214.36M-2.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Spyre Therapeutics, Inc. profitable?
- Spyre Therapeutics, Inc. is not currently profitable: it reported a net loss of $179.4M over the trailing twelve months, a -52939.7% net margin.
- What is Spyre Therapeutics, Inc.'s earnings per share?
- Spyre Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-2.12.
- Where does Spyre Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.